Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Latest news

2/25/2020 2019 Ranking of Russian Pharmaceutical Distributors

Despite the relatively good results of last year, the overall profitability in the supply chain leaves much to be desired. First of all, this concerns the retail segment of the market, since the growth in 2019 is significantly lower than inflation, without any positive outlook, apart from the coronavirus, which might somewhat stabilize the situation. In addition, the Russian pharmaceutical retail market decided to follow the “big retail” and enter the era of global transformation together with the online segment.

2/20/2020 2019 Ranking of Russian Pharmacy Chains

The coronavirus epidemic in China has definitely become one of the central issues of the early 2020. It is difficult to predict how the situation will evolve, and what consequences the healthcare system and the economy will have to face. However, the aspect of a certain cultural phenomenon in our country, formed by COVID-2019, is hard to ignore.

2/14/2020 Database Update: Pharmaceutical Drug Production in Russia (December 2019)

In 2019, Russia manufactured 425.3 bln RUB worth of pharmaceutical drugs (manufacturers’ dispatch prices, VAT included), which is in monetary terms (rubles) 26.6% higher than that in 2018. The results are the highest since the financial crisis between 2015 and 2016. The dynamics in physical terms are +7.4% in units and +6.4% in minimum dosage units (MDU), with 4.5 bln units of ready-made pharmaceuticals, or 75 bln MDUs.

2/5/2020 Database Update: Veterinary Drug Retail Sales Audit in Russia (December 2019 and Full Year)

The volume of Russian households’ purchases of veterinary drugs amounted to 20.6 bln RUB (retail prices, VAT included) in 2019. The volume of purchases in physical terms is over 110 mln units (or over 199 mln MDUs), including veterinary products sold in single-unit packages.

2/3/2020 Survey by RNC Pharma and Doktor Na Rabote (Doctor at Work): 43% Believe Fundamental Changes Only Possible after Decision-Making and Responsibility System Is Revised

Despite a flurry of criticism of the activities of the former members of the Ministry of Health, only 5% of doctors believe that the new Government of the Russian Federation will make fundamental changes to the key issues of the organization of the health system, according to an online survey by the RNC Pharma analyst company and the Doktor Na Rabote (Doctor at Work) social media service for doctors. Most respondents (43%) are sure that not only personnel changes, but also a revision of the decision-making and responsibility system is necessary to change the current situation.

All news [155]

Our competences

RNC Pharma is focused on providing information about development trends of Russian pharmaceutical market infrastructure component. Our experts also provide services on strategic marketing, such as forecasting, business planning, etc.